FDA Grants EUA for Cardiac Monitoring in COVID-19 Patients

VitalConnect® announced it was granted Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) as part of the response to the COVID-19 pandemic. The FDA EUA will further enhance the capabilities of the VitalPatch and continuous patient monitoring technology, the Vista Solution.

Under the EUA, the VitalPatch is now authorized to detect changes in the QT interval of hospitalized patients undergoing drug treatment for COVID-19. Drugs such as Hydroxychloroquine and Chloroquine, being used to treat COVID-19, can cause prolongation of QT intervals for patients and may lead to life-threatening arrhythmias. VitalConnect QT interval detection capabilities help enable clinicians remotely and continuously monitor patients in real-time who may have, or develop, an elongation of QT interval as a result of their COVID-19 treatment.

"COVID-19 presents a myriad of symptoms and clinicians need access to medical devices that allow them to monitor and manage those symptoms in real-time in order to create the most appropriate treatment plans for each individual," said Dr. Joe Roberson, Chief Medical Officer of VitalConnect. "The enhancement of the VitalPatch receiving Emergency Use Authorization for QT-interval detection will enable this platform to further support clinicians who are on the frontlines of treating this virus."

As clinicians recognize and analyze the impact of COVID-19 on the heart, the ability to monitor other key vital signs provides critical information needed to develop effective treatment plans. Vista Solution, with the VitalPatch and optional 3rd party devices, measures 11 physiological vitals continuously and in real-time including body temperature, heart rate, heart rate variability, respiratory rate, and blood oxygen saturation levels. The VitalPatch is the first and only biosensor capable of monitoring such a broad set of patient vitals as well as detecting QT interval changes.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

PharmaSources.com is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.